Nonetheless, we showed that a HER2-targeting TVD–Fab penetrated a HER2-expressing orthotopic breast cancer xenograft more efficiently than its DVD–IgG1 counterpart when tested one day after administration, suggesting that tumor tissue accumulation can be achieved with a qod or biw dosing regimen. The gene discussed is ERBB2; the disease is breast cancer.